Importantly, pancreatic cancer mouse models have demonstrated that targeting CTLA4 in Tregs increases the infiltration of CD4+ T cells recruited to the tumor, suggesting that targeting Tregs is important for PDAC immunotherapy [45]. The gene discussed is CTLA4; the disease is neoplasm.